Amgen announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company’s total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.

The $1 billion facility will incorporate cutting-edge technologies and sustainable practices. In tandem with the existing facility, these investments will create 370 new jobs in the region, supporting the area’s biomanufacturing hub.

North Carolina’s Economic Investment Committee approved a Job Development Investment Grant that will reimburse Amgen up to $4.9 million yearly across the grant’s 12-year duration. The project is expected to grow the state’s economy by $3.6 billion throughout that period. When fully operational, more than 720 jobs will be generated across both facilities. Construction began in March 2022, and that plant will be operational in 2026.

The firm owns nearly 109 acres at 4130 Friendship Road, and the two plants are slated for delivery there.